Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-0584
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma ; volume:93 ; number:3 ; day:17 ; month:8 ; year:2013 ; pages:403-409 ; date:3.2014
Annals of hematology ; 93, Heft 3 (17.8.2013), 403-409, 3.2014
- Creator
-
Vacirca, Jeffrey L.
Acs, Peter. I.
Tabbara, Imad A.
Rosen, Peter. J.
Lee, Peter
Lynam, Eric
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00277-013-1879-x
- URN
-
urn:nbn:de:101:1-2019101321242006534042
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:23 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Vacirca, Jeffrey L.
- Acs, Peter. I.
- Tabbara, Imad A.
- Rosen, Peter. J.
- Lee, Peter
- Lynam, Eric
- SpringerLink (Online service)
Other Objects (12)
Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma
Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphoma
Management of relapsed-refractory diffuse large B cell lymphoma
Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study
Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial
Hypofractionated radiotherapy for refractory or relapsed aggressive B-cell lymphoma in the rituximab era
Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland
Correction to: Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial
Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study
Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma
Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies
Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma
Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphoma
Management of relapsed-refractory diffuse large B cell lymphoma
Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study
Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial
Hypofractionated radiotherapy for refractory or relapsed aggressive B-cell lymphoma in the rituximab era
Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland
Correction to: Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial
Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study
Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma
Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies
Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma
Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphoma
Management of relapsed-refractory diffuse large B cell lymphoma
Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study
Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial
Hypofractionated radiotherapy for refractory or relapsed aggressive B-cell lymphoma in the rituximab era
Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland
Correction to: Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial
Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study
Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma